Press release
Hepatitis C Treatment Market Estimated to Be Valued at US$ 71.13 Bn by the End of 2024
Market dynamics
Growth of the global hepatitis C treatment market is primarily driven by factors such as increase in the prevalence of hepatitis C infections in the U.S. and Canada and rising per capita healthcare expenditure across the globe. Also government initiatives to control infection and various private NGOs creating awareness about treatment is also fueling the market growth. However, high cost associated with hepatitis C treatment drugs and lack of awareness about hepatitis C infection in the regions of Asia Pacific, Middle East and Africa, and Latin America is expected to impede growth of the global hepatitis C treatment market.
Request to Download and View Full TOC @ https://www.persistencemarketresearch.com/market-research/hepatitis-c-treatment-market/toc
Market forecast
By drug class, the market is segmented into HCV Protease Inhibitors, HCV Polymerase Inhibitors, HCV NS5A Inhibitors, Combination Therapy and Interferon & Antiviral which is again sub-divided into various drugs sub segments. The combination segment is expected to contribute a maximum share to the global hepatitis C treatment market and register the fastest CAGR of 13.9% during the forecast period. By distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Among these, the hospital pharmacies segment is anticipated to be dominant throughout the forecast period and is projected to account for about 43.7% share of the total global hepatitis C treatment market revenue by 2024. The hospital pharmacies segment is anticipated to emerge as the most attractive segment in the global hepatitis C treatment market owing to growing instances of hospitalization and improved accessibility and services. The online pharmacies segment is expected to register the fastest CAGR during the forecast period and is estimated to create absolute $ opportunity of US$ 713.8 Mn in 2017 over 2016. The online pharmacies segment is expected to witness significant growth during the forecast period and this can be attributed to high availability of hepatitis C treatment drugs and discounts provided by online pharmacies.
Request to View Sample Report @ https://www.persistencemarketresearch.com/samples/3602
This report covers global and regional trends along with an analysis of the market potential. North America is estimated to account for 45% share in the global hepatitis C treatment market by 2016, whereas Asia Pacific is projected to grow at a healthy CAGR of 14.8% due to increasing awareness about hepatitis C infections. Europe region is expected to account for 19.6% share in the global hepatitis C treatment market by 2016 end. Latin America was valued at US$ 2,915.8 Mn in 2015 and is estimated to reach US$ 3,311.1 Mn by 2016, with a Y-o-Y growth of 13.6% over 2015–2016. The Middle East and Africa region was valued at US$ 1,792.5 Mn in 2015 and is estimated to reach US$ 1,988.1 Mn by 2016.
Browse Full Report @ https://www.persistencemarketresearch.com/market-research/hepatitis-c-treatment-market.asp
View Report Table of Contents, Figures, and Tables
Competitive landscape
The global hepatitis C treatment market report features some of the top companies dominating in the global market. Key market players analyzed in the report include Merck & Co., Inc., Bristol-Myers Squibb Company, AbbVie Inc., Gilead Sciences, Inc., Kadmon Holdings, Inc., Johnson & Johnson, F Hoffmann-La Roche Ltd, and Merck & Co., Inc. Leading companies functioning in the global hepatitis C treatment market are focusing on collaborating with healthcare solutions and services providers in order to advance operational efficiencies and provide improved patient care.
Buy Full Hepatitis C Treatment Market Report @ https://www.persistencemarketresearch.com/checkout/3602
ABOUT US:
Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance. To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.
CONTACT:
Persistence Market Research
305 Broadway
7th Floor, New York City,
NY 10007, United States,
USA – Canada Toll Free: 800-961-0353
Email: sales@persistencemarketresearch.com
Web: http://www.persistencemarketresearch.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hepatitis C Treatment Market Estimated to Be Valued at US$ 71.13 Bn by the End of 2024 here
News-ID: 767176 • Views: …
More Releases from Persistence Market Research PVT. LTD.
Battery Material Market is projected to reach a valuation of US$ 110.02 billion …
The battery material market has witnessed significant growth in recent years, driven by the increasing demand for batteries in various applications. According to recent studies, the market was valued at USD 42.1 billion in 2022 and is projected to reach USD 110.02 billion by 2027, growing at a CAGR of 14.1% during the forecast period.
Click Here to Get Free Sample Copy of this Report@https://www.persistencemarketresearch.com/samples/10801
The battery material market encompasses a wide…
Automated Intralogistics Material Handling Solutions Market to Hit US$ 219.3 b …
Automated intralogistics material handling solution sales are anticipated to achieve a global market value of US$ 55.9 billion in 2023 and to grow steadily at a CAGR of 14.8% to reach US$ 219.3 billion by 2033.
The global intralogistics material handling solutions market is experiencing a revolution with the introduction of automated systems. Automation has become a game-changer, offering greater efficiency and productivity to businesses across the globe. The market for automated intralogistics material handling solutions is projected to witness impressive growth in the coming years.
Click Here to Get Free Sample Copy of this Report@https://www.persistencemarketresearch.com/samples/32829
The key drivers for the growth of the automated intralogistics material handling…
Cold Chain Market is Encouraged to Reach USD 474.29 billion by 2028
The global cold chain market size was valued at USD 211.77 billion in 2020 and is expected to reach USD 474.29 billion by 2028, growing at a CAGR of 9.7% from 2021 to 2028. The growth is driven by increasing demand for perishable goods, globalization of the food trade, and technological advancements in cold chain logistics.
Click Here to Get Free Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/3177
The cold chain market refers…
Automated Intralogistics Material Handling Solutions Market Value to Hit US$ 219 …
𝐀𝐮𝐭𝐨𝐦𝐚𝐭𝐞𝐝 𝐈𝐧𝐭𝐫𝐚𝐥𝐨𝐠𝐢𝐬𝐭𝐢𝐜𝐬 𝐌𝐚𝐭𝐞𝐫𝐢𝐚𝐥 𝐇𝐚𝐧𝐝𝐥𝐢𝐧𝐠 𝐒𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐬 𝐌𝐚𝐫𝐤𝐞𝐭
𝐈𝐧 𝟐𝟎𝟐𝟑, 𝐬𝐚𝐥𝐞𝐬 𝐨𝐟 𝐚𝐮𝐭𝐨𝐦𝐚𝐭𝐞𝐝 𝐢𝐧𝐭𝐫𝐚𝐥𝐨𝐠𝐢𝐬𝐭𝐢𝐜𝐬 𝐦𝐚𝐭𝐞𝐫𝐢𝐚𝐥 𝐡𝐚𝐧𝐝𝐥𝐢𝐧𝐠 𝐬𝐨𝐥𝐮𝐭𝐢𝐨𝐧𝐬 𝐢𝐧 𝐠𝐥𝐨𝐛𝐚𝐥 𝐦𝐚𝐫𝐤𝐞𝐭 𝐢𝐬 𝐞𝐱𝐩𝐞𝐜𝐭𝐞𝐝 𝐭𝐨 𝐫𝐞𝐚𝐜𝐡 𝐔𝐒$ 𝟓𝟓.𝟗 𝐁𝐧 𝐚𝐧𝐝 𝐢𝐬 𝐩𝐫𝐨𝐣𝐞𝐜𝐭𝐞𝐝 𝐭𝐨 𝐞𝐱𝐩𝐚𝐧𝐝 𝐬𝐭𝐞𝐚𝐝𝐢𝐥𝐲 𝐚𝐭 𝐚 𝐂𝐀𝐆𝐑 𝐨𝐟 𝟏𝟒.𝟖% 𝐭𝐨 𝐫𝐞𝐚𝐜𝐡 𝐚 𝐦𝐚𝐫𝐤𝐞𝐭 𝐯𝐚𝐥𝐮𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐜𝐥𝐨𝐬𝐞 𝐭𝐨 𝐔𝐒$ 𝟐𝟏𝟗.𝟑 𝐁𝐧 𝐛𝐲 𝟐𝟎𝟑𝟑.
The demand in Germany is expected to increase by 15.7% CAGR from 2024 to 2033 on a value basis. U.S., China, and Germany are the leading countries in the…
More Releases for Hepatitis
Is Hepatitis A Vaccine Required?
Hepatitis A Vaccine Market describes its growth, size, share, Forecast and trends to 2025
Hepatitis A vaccine is a vaccine which is against the hepatitis A virus. The Hepatitis A vaccine is available for long-term prevention of HAV infection, Minimum age for HAV vaccination is 1 year.
Two types of HAV vaccines are currently available internationally:
1. Formaldehyde-inactivated vaccines: Inactivated HAV vaccines are used in most countries. Monovalent inactivated HAV vaccines are available…
Hepatitis Drugs Market Is Growing Due to Increasing R&D Investments on Hepatitis …
The global hepatitis drugs market is growing due to increasing incidences of hepatitis and increasing support from government organizations. In addition, the growing geriatric population, and increasing R&D investments on hepatitis research and drug discovery are also driving the growth of the global hepatitis drugs market.
Access Detailed Report Summary: https://www.psmarketresearch.com/market-analysis/hepatitis-drugs-market
Among the various types, the hepatitis C segment is expected to be the largest segment, and expected to witness the fastest…
Hepatitis B Therapeutics Market Is Driven by Rising Incidence of Hepatitis B In …
Hepatitis B is a life threatening liver infection caused by hepatitis B virus. Adults who get affected by hepatitis B virus for a short time and then get cured is known as acute hepatitis B. Infection that lasts for a long time is known as chronic hepatitis B. Vaccine is the most preferred choice of doctors and physicians to protect people from the disease. The vaccine prevents the infection and…
Hepatitis E Hyperendemicity to Drive Hepatitis E Diagnostic Tests Market Growth
Global Hepatitis E Diagnostic Tests Market: Snapshot
The growing incidence of hepatitis E, a liver disease caused by infection due to the virus hepatitis E virus (HEV), is a leading cause of morbidity and mortality worldwide. There is increasing prevalence of hepatitis E in resource-limited region, such as various countries of Asia Pacific. The people of these regions suffer with frequent water contamination and have limited access to sanitation and hygiene,…
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
1. Introduction to Hepatitis Disease
1.1 Prologue
1.1.1 History of Hepatitis
1.1.2 Causes of Hepatitis Disease
1.2 Types of Viruses which are Responsible for Hepatitis Disease
2. Global Prevalence of Hepatitis Infection
3. Available Drug Classes for Hepatitis Disease Treatment
3.1 Interferon Alfa Therapy
3.2 Protease Inhibitors Therapy
3.3 Polymerase…
Hepatitis C Drug Pipeline Analysis
“Hepatitis C Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drug profiles being developed for the treatment of Hepatitis C. Research report covers all the ongoing drug development in various phases. Each drug profiles include detailed information like: Originator, Owner, Collaborator, Technology Provider, Licensee, Development Phase, Development Indications, Mechanism of Action, Chemical Formula, Country of Development and detailed analysis on the development process. Insight for each…
